In Memory
David
Patient Information
Age: 32
Sex: Male
Diagnosed: 3/02
Location: Virginia
Diagnosis: Stage IV DSRCT.
Hospital: Brigham and Women's Hospital, Mass.
- Oncologist Jeffrey Morgan, MD - Dana Farber Sacroma Center
- Surgeon Monica Bertagnolli, MD
Passed away: 10/19/07
Treatment
Chemotherapy
Clinical Trial - Perifosine - had to stop as it made him sick
Clinical Trial - Phase III Trabectedin ET743 (Yondelis) at Dana Farber in Boston. Had one round of treatment.
Surgery - Tumors had grown to a point where blockage occurred. The hospital wanted to do surgery to relieve the blockage, but not address the tumors. Which meant that the tumors would have continue to grow again and cause the same problem. Dana-Farber agreed to do the surgery on March 27th. They removed 80% tumors and small amounts of intestine, colon and rectum. Now has a colostomy.
Clinical Trial - Sorafenib at Dana Farber in Boston.
Clinical Trial - A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
Time Line
| Date | Test | Treatment | Chemicals | Result | |
|---|---|---|---|---|---|
| 3/02 | 0 | 0 | 0 | Tumors in abdomen and pelvis | |
| 4/02 | 0 | 0 | 0 | 0 | |
| 5/02 | 0 | 0 | 0 | 0 | |
| 6/02 | 0 | 0 | 0 | 0 | |
| 7/02 | 0 | 0 | 0 | 0 | |
| 8/02 | 0 | 0 | 0 | 0 | |
| 9/02 | 0 | 0 | 0 | 0 | |
| 10/02 | 0 | 0 | 0 | 0 | |
| 11/02 | 0 | 0 | 0 | 0 | |
| 12/02 | 0 | 0 | 0 | 0 | |
| 1/03 | 0 | 0 | 0 | 0 | |
| 2/03 | 0 | 0 | 0 | 0 | |
| 3/03 | 0 | 0 | 0 | 0 | |
| 4/03 | 0 | 0 | 0 | 0 | |
| 5/03 | 0 | 0 | 0 | 0 | |
| 6/03 | 0 | 0 | 0 | 0 | |
| 7/03 | 0 | 0 | 0 | 0 | |
| 8/03 | 0 | 0 | 0 | 0 | |
| 9/03 | 0 | 0 | 0 | 0 | |
| 10/03 | 0 | 0 | 0 | 0 | |
| 11/03 | 0 | 0 | 0 | 0 | |
| 12/03 | 0 | 0 | 0 | 0 | |
| 1/04 | 0 | 0 | 0 | 0 | |
| 2/04 | 0 | 0 | 0 | 0 | |
| 3/04 | 0 | 0 | 0 | 0 | |
| 4/04 | 0 | 0 | 0 | 0 | |
| 5/04 | 0 | 0 | 0 | 0 | |
| 6/04 | 0 | 0 | 0 | 0 | |
| 7/04 | 0 | 0 | 0 | 0 | |
| 8/04 | 0 | 0 | 0 | 0 | |
| 9/04 | 0 | 0 | 0 | 0 | |
| 10/04 | 0 | 0 | 0 | 0 | |
| 11/04 | 0 | 0 | 0 | 0 | |
| 12/04 | 0 | 0 | 0 | 0 | |
| 1/05 | 0 | 0 | 0 | 0 | |
| 2/05 | 0 | 0 | 0 | 0 | |
| 3/05 | 0 | 0 | 0 | 0 | |
| 4/05 | 0 | 0 | 0 | 0 | |
| 5/05 | 0 | 0 | 0 | 0 | |
| 6/05 | 0 | 0 | 0 | 0 | |
| 7/05 | 0 | 0 | 0 | 0 | |
| 8/05 | 0 | 0 | 0 | 0 | |
| 9/05 | 0 | 0 | 0 | 0 | |
| 10/05 | 0 | 0 | 0 | 0 | |
| 11/05 | 0 | 0 | 0 | 0 | |
| 12/05 | 0 | 0 | 0 | 0 | |
| 1/06 | 0 | 0 | 0 | 0 | |
| 2/06 | 0 | 0 | 0 | 0 | |
| 3/27/06 | 0 | Debulking Surgery | 0 | Removed 80% of tumors. | |
| 4/06 | CT | 0 | 0 | No visible tumors | |
| 05/06 | 0 | Clinical Trial Phase III | Yondelis ET-743 | 0 | |
| 6/06 | 0 | Clinical Trial Phase III | Yondelis ET-743 | 0 | |
| 7/06 | 0 | Clinical Trial Phase III | Yondelis ET-743 | 0 | |
| 8/06 | 0 | Clinical Trial | Sorafenib | 0 | |
| 9/06 | 0 | Clinical Trial | Sorafenib | 0 | |
| 10/06 | 0 | Clinical Trial | Sorafenib | 0 | |
| 11/06 | CT | Clinical Trial | Sorafenib | Some shrinkage, with no new growth. | |
| 12/06 | 0 | Clinical Trial | Sorafenib | 0 | |
| 1/07 | 0 | Clinical Trial | Sorafenib | 0 | |
| 2/12/07 | CT | Clinical Trial | Sorafenib | Slight increase with no new disease. | |
| 3/07 | 0 | Clinical Trial | 0 | 0 | |
| 4/07 | 0 | Clinical Trial | 0 | 0 | |
| 5/07 | 0 | Clinical Trial | 0 | 0 | |
| 6/07 | 0 | Clinical Trial | 0 | 0 | |
| 7/07 | 0 | Clinical Trial | 0 | 0 | |
| 8/07 | 0 | Clinical Trial | Phase 1 Clinical Study AMG 479 | 0 | |
| 9/07 | 0 | Clinical Trial | Phase 1 Clinical Study AMG 479 | Progression of disease. Stopping treatment. | |
| 10/19/07 | 0 | 0 | 0 | Passed away | = |
5yr
[BACK]
